Warm antibody autoimmune hemolytic anemia

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Retrieved on: 
Friday, April 9, 2021

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Retrieved on: 
Friday, April 9, 2021

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Retrieved on: 
Friday, March 26, 2021

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Retrieved on: 
Wednesday, March 17, 2021

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Retrieved on: 
Friday, March 5, 2021

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • Glancy Prongay & Murray LLP, Los Angeles

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Retrieved on: 
Wednesday, March 3, 2021

Investors suffering losses on their Immunovant investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Immunovant investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Retrieved on: 
Monday, March 1, 2021

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) Investors

Retrieved on: 
Wednesday, February 24, 2021

Immunovant investors have until April 20, 2021 to file a lead plaintiff motion.

Key Points: 
  • Immunovant investors have until April 20, 2021 to file a lead plaintiff motion.
  • If you are a shareholder who suffered a loss, click here to participate.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).

Shareholder Alert: Robbins LLP Announces That Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) is Being Sued for Misleading Shareholders

Retrieved on: 
Tuesday, February 23, 2021

The Company is developing IMVT-1401, which is in Phase IIa clinical trials for the treatment of Graves' ophthalmopathy.

Key Points: 
  • The Company is developing IMVT-1401, which is in Phase IIa clinical trials for the treatment of Graves' ophthalmopathy.
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia.
  • As a result of the merger, HSAC acquired all shares of Immunovant Sciences and Immunovant Sciences became a wholly owned subsidiary of HSAC.
  • On this news, Immunovant's stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021.

Global Warm Autoimmune Hemolytic Anemia Market to 2030 - Insights, Epidemiology and Forecast - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 19, 2020

The "Warm Autoimmune Hemolytic Anemia (WAIHA) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Warm Autoimmune Hemolytic Anemia (WAIHA) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Warm Autoimmune Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies.
  • The Warm Autoimmune Hemolytic Anemia (WAIHA) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
  • To understand the future market competition in the Warm Autoimmune Hemolytic Anemia market.